Drug Approval | June 02, 2025
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
These observations are procedural in nature and none of them are related to data integrity
The FDA issued Form 483 with one observation related to building and facility management
The inspection concluded with 6 observations and none of them were related to Data Integrity
Raichur site is the group’s largest API facility and part of a wider network of seven sites
The inspection has concluded with four observations
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
The inspection was successfully completed
Subscribe To Our Newsletter & Stay Updated
